Comments
Multinational drug-maker Eli Lilly India and Lupin Ltd have entered into an alliance to promote and distribute Lilly's insulin range, Huminsulin.
Lupin will promote and distribute the range of products in India and Nepal, doubling the number of sales representatives behind the diabetes-care product, a joint-note from the companies said.
The collaboration will also double the current customer base and approximately 45,000 doctors will now be called on as a result of the new partnership, they added.
India is estimated to have 51 million people with diabetes and this is expected to go up to 85 million by 2030, or about one-fifth the global number of diabetes patients.
Lilly expects to increase access to Huminsulin products through its relationship with Lupin India, bringing one of the most basic and proven therapies for diabetes treatment to more patients, the company said. Lupin's India formulation business will deploy 300 medical representatives to provide education and resources to physicians and patients.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.